{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:04:10Z","timestamp":1774940650232,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The Immunotherapy of the M.D. Anderson Symptom Inventory for Early-Phase Trials module (MDASI-Immunotherapy EPT) was initially developed to assess the severity of symptoms in tumor patients undergoing immunotherapy. However, in the application of this scale, it was observed that the scale did not cover the wide range of symptoms patients reported. Therefore, the scale was revised to reflect such symptoms more comprehensively based on previous studies and expert advice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive approach was employed to identify symptoms associated with immunotherapy, encompassing a systematic literature review, semi-structured interviews with clinicians and patients, Delphi methodology, and cognitive interviews. Based on item analysis and assessments of reliability and validity, 15 immunotherapy-specific items were ultimately selected for inclusion in the revised MDASI scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Through systematic literature review, semi-structured interviews, Delphi consensus, and cognitive interviews, 17 new immunotherapy-specific symptoms were identified. Following item analysis in Study 2.1 (n=396), 9 items were excluded, resulting in a final 34-item scale comprising 13 core symptoms, 15 immunotherapy-specific items, and 6 interference items. Exploratory factor analysis in an independent sample (Study 2.2, n=418) revealed a 6-factor structure (skin symptoms, digestive system symptoms, cardiac symptoms, hepatobiliary system symptoms, extremity edema and musculoskeletal symptoms, pain and fever dimensions) explaining 77.59% of the total variance. The revised MDASI-Immunotherapy EPT demonstrated excellent internal consistency reliability, with Cronbach\u2019s alpha values of 0.917 for the core subscale, 0.878 for the immunotherapy module, and 0.910 for the interference subscale. Criterion validity analysis using Spearman\u2019s correlations revealed significant associations with FACT-G physical well-being domain (\u03c1 = 0.551-0.674, p &amp;lt; 0.01). Subgroup analyses confirmed consistent psychometric properties across urban and rural populations and across major cancer types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The modified MDASI-Immunotherapy EPT is a valid, reliable, and sensitive tool for measuring symptomatic toxicity in patients receiving immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1722663","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:32:55Z","timestamp":1774935175000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychometric validation of Chinese version of the immunotherapy of the M.D. Anderson Symptom Inventory for Early-Phase Trials module in a multi-cancer cohort"],"prefix":"10.3389","volume":"17","author":[{"given":"Tiantian","family":"Fan","sequence":"first","affiliation":[{"name":"Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangzheng","family":"Wu","sequence":"additional","affiliation":[{"name":"Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoma","family":"Lacuo","sequence":"additional","affiliation":[{"name":"School of Nursing, Sun Yat-sen University","place":["Guangzhou, Guangdong, China"]},{"name":"Department of Gastrointestinal Surgery, The Seventh Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center","place":["Guangzhou, Guangdong, China"]},{"name":"Unit of Psychiatry, Department of Public Health and Medicinal Administration, & Institute of Translational Medicine, Faculty of Health Sciences, University of Macau","place":["Macao, Macao SAR, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111777","article-title":"Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook","volume":"8","author":"M\u00f6hn","year":"2019","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41698-021-00223-x","article-title":"Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types","volume":"5","author":"Wang","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"106452","DOI":"10.1016\/j.intimp.2020.106452","article-title":"Effectivity and safety of PD-1\/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials","volume":"84","author":"Shi","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coph.2016.06.008","article-title":"Psychological side effects of immune therapies: symptoms and pathomechanism","volume":"29","author":"Kovacs","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000931","article-title":"Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory","volume":"8","author":"Mendoza","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12912-023-01217-9","article-title":"Translation and validation of chinese version of MDASI immunotherapy for early-phase trials module: a cross-sectional study","volume":"22","author":"Wu","year":"2023","journal-title":"BMC Nurs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.21037\/atm-22-1284","article-title":"Severe immune-related hepatitis and myocarditis caused by PD-1 inhibitors in the treatment of triple-negative breast cancer: a case report","volume":"10","author":"Yang","year":"2022","journal-title":"Ann Transl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphys.2021.11.002","article-title":"Research Note: Thematic analysis in qualitative research","volume":"68","author":"Ayre","year":"2022","journal-title":"J Physiother"},{"key":"B10","volume-title":"Scale Development: Theory and Applications","author":"DeVellis","year":"2021"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1177\/0011000006288127","volume-title":"Scale Development Research: A Content Analysis and Recommendations for Best Practices","author":"Worthington","year":"2006"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02775","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"41","author":"Cella","year":"2023","journal-title":"J Clin Oncol"},{"key":"B13","first-page":"77","article-title":"Cancer patient quality of life assessment scale FACT-G Chinese version evaluation","volume":"21","author":"Chonghua","year":"2006","journal-title":"J Pract Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.12534","article-title":"Association of sex, age, and eastern cooperative oncology group performance status with survival benefit of cancer immunotherapy in randomized clinical trials: A systematic review and meta-analysis","volume":"3","author":"Yang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B15","volume-title":"Structural Equation Model-AMOS Operation and Application","author":"Wu","year":"2010"},{"key":"B16","volume-title":"Basic Biostatistics: Statistics for Public Health Practice","author":"Gerstman","year":"2008"},{"key":"B17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","article-title":"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients\u2019 health-related quality of life","volume":"176","author":"Schulz","year":"2022","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/1740774519836991","article-title":"Patient reported outcomes in anti-PD-1\/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions","volume":"16","author":"King-Kallimanis","year":"2019","journal-title":"Clin Trials"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/genes15020177","article-title":"Cardiac and nephrological complications related to the use of antiangiogenic and anti-programmed cell death protein 1 receptor\/programmed cell death protein 1 ligand therapy","volume":"15","author":"Stachyra-Strawa","year":"2024","journal-title":"Genes-Basel"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.180870","article-title":"Adverse events associated with immune checkpoint inhibitor treatment for cancer","volume":"191","author":"Esfahani","year":"2019","journal-title":"Can Med Assoc J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2025.0346","article-title":"Current status of management of immune-related adverse events and practical needs for oncologist education","volume":"22","author":"Tian","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ijnss.2018.11.005","article-title":"Reliability and validity of Chinese version of a tool to assess the quality of life in idiopathic pulmonary fibrosis in patients with interstitial lung disease","volume":"6","author":"Pan","year":"2019","journal-title":"Int J Nurs Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0297","article-title":"A systematic review of health-related quality of life reporting in ovarian cancer phase III clinical trials: room to improve","volume":"23","author":"Wilson","year":"2018","journal-title":"Oncologist"},{"key":"B25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1186\/s12885-022-09995-2","article-title":"Translation and validation of M.D. Anderson Symptom Inventory-Thyroid Cancer module in Chinese thyroid cancer patients: a cross-sectional and methodological study","volume":"22","author":"Hu","year":"2022","journal-title":"BMC Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2016.10.360","article-title":"A cross-sectional study on the symptom burden of patients with spinal tumor: validation of the Chinese version of the M.D. Anderson symptom inventory-spine tumor module","volume":"53","author":"Xu","year":"2017","journal-title":"J Pain Symptom Manag"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2023-112681","article-title":"Guidelines for the development and validation of patient-reported outcome measures: a scoping review","volume":"29","author":"Jung","year":"2024","journal-title":"BMJ Evid-Based Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1722663\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:32:57Z","timestamp":1774935177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1722663\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1722663"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1722663","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1722663"}}